BCG (Bacille Calmette-Guérin) is the only WHO-approved tuberculosis vaccine and is given to infants, but has proven ineffective in adults. Enter GlaxoSmithKline ($GSK), which, along with Aeras and Kenya Medical Research Institute, will roll their candidate in Phase IIb trials in Kenya, Standard Digital reports. The multicountry trials are also taking place in South Africa and Zambia and will evaluate the safety of the candidate. The Kenyan arm is expected to enroll at least 450 Kenyans aged 18 to 50, and is expected to be completed in 2018. The goal is to develop a vaccine that will prevent the progression of latent TB to active TB. More